Evidence for PTEN-independent Akt activation and Akt-independent p27Kip1 expression in advanced bladder cancer

Oncology Letters

Volumn 2, Issue 6, 2011, Pages 1089-1093

  Mundhenk, J ^a   Hennenlotter, J ^a   Zug, L ^a   Alloussi, S H ^a   Todenhoefer, T ^a   Gakis, G ^a   Aufderklamm, S ^a   Scharpf, M ^a   Kuehs, U ^a   Stenzl, A ^a   Schwentner, Christian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Akt; Biomarker; Bladder cancer; p27Kip1; PTEN; Targeted therapy; Tissue microarray

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; CORRELATION ANALYSIS; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 80052731901     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.374     Document Type: Article

References (36)

1. Parkin M, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19: 666-675, 2001.
3. Netto G and Epstein J: Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology 42: 384-394, 2010.
4. Altomare D and Testa J: Perturbations of the AKT signaling pathway in human cancer. Oncogene 24: 7455-7464, 2005.
5. Samuels Y and Ericson K: Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18: 77-82, 2006.
6. Sherr C and Roberts J: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999.
7. Azim H, Azim H and Escudier B: Targeting mTOR in cancer: renal cell is just a beginning. Target Oncol 5: 269-280, 2010.
8. Mass R, Press M, Anderson S, et al: Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 6: 240-246, 2005.
9. Graff JR, Konicek BW, McNulty AM, et al: Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 275: 24500-24505, 2000.
10. Merseburger A, Hennenlotter J, Kuehs U, et al: Activation of PI3K is associated with reduced survival in renal cell carcinoma. Urol Int 80: 372-377, 2008.
11. Hennenlotter J, Ohneseit P, Simon P, et al: PTEN and p27Kip1 are not downregulated in the majority of renal cell carcinomas-implications for Akt activation. Oncol Rep 19: 1141-1147, 2008.
12. Kurose K, Zhou X-P, Araki T, Cannistra S, Maher E and Eng C: Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 158: 2097-2106, 2001.
13. Kallioniemi OP, Wagner U, Kononen J and Sauter G: Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 10: 657-662, 2001.
14. Theodorescu D, Broder SR, Boyd JC, Mills SE and Frierson HF: Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 80: 2109-2119, 1997.
15. Blain S, Scher H, Cordon-Cardo C and Koff A: p27 as a target for cancer therapeutics. Cancer Cell 3: 111-115, 2003.
16. Chiarle R, Pagano M and Inghirami G: The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res 3: 91-94, 2001.
17. Seki R, Ohshima K, Fujisaki T, et al: Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma: effects of rituximab. Ann Oncol 21: 833-841, 2010.
18. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JFR and Ellis IO: The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 204: 93-100, 2004.
19. Cantley LC and Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96: 4240-4245, 1999.
20. Khaleghpour K, Li Y, Banville D, Yu Z and Shen SH: Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 25: 241-248, 2004.
21. Shi W, Zhang X, Pintilie M, et al: Dysregulated PTEN-PKB and negative receptor status in human breast cancer. Int J Cancer 104: 195-203, 2003.
22. Yoganathan TN, Costello P, Chen X, et al: Integrin-linked kinase (ILK): a 'hot' therapeutic target. Biochem Pharmacol 60: 1115-1119, 2000.
23. Persad S, Attwell S, Gray V, et al: Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 97: 3207-3212, 2000.
24. Widenmaier S, Sampaio A, Underhill M and McIntosh C: Noncanonical activation of Akt/protein kinase B in {beta}-cells by the incretin hormone glucose-dependent insulinotropic polypeptide. J Biol Chem 284: 10764-10773, 2009.
25. Trotman L, Alimonti A, Scaglioni PP, Koutcher J, Cordon-Cardo C and Pandolfi PP: Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441: 523-527, 2006.
26. Blain S and Massagué J: Breast cancer banishes p27 from nucleus. Nat Med 8: 1076-1078, 2002.
27. Connor M, Kotchetkov R, Cariou S, et al: CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis. Mol Biol Cell 14: 201-213, 2003.
28. Liang J, Zubovitz J, Petrocelli T, et al: PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8: 1153-1160, 2002.
29. Shin I, Yakes M, Rojo F, et al: PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization. Nat Med 8: 1145-1152, 2002.
30. Capodanno A, Camerini A, Orlandini C, et al: Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. Hum Pathol 40: 1408-1417, 2009.
31. Pantuck A, Seligson D, Klatte T, et al: Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer 109: 2257-2267, 2007.
32. Chen M, Gu J, Delclos G, et al: Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. Carcinogenesis 31: 1387-1391, 2010.
33. Shariat S, Ashfaq R, Sagalowsky A and Lotan Y: Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 177: 481-487, 2007.
34. Laé M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P and Vieillefond A: Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 21: 815-819, 2010.
35. Havaleshko D, Smith SC, Cho H, et al: Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. Neoplasia 11: 1185-1193, 2009.
36. Miyake M, Ishii M, Koyama N, et al: 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. J Pharmacol Exp Ther 332: 795-802, 2010.